Skip to main content

Israeli Start-Up Raises $7.1M in Private Financing

NEW  YORK, Nov. 7 – Glycominds of Israel has raised $7.1 million in a private financing round, the company said.

The company, which is developing technologies for analyzing the interactions between complex carbohydrates, or glycans, received the funding from Israel's Millennium Materials Technologies Fund, Schott Glas, a German manufacturer of special materials, and other undisclosed venture capital funds.

Glycominds has developed the GlycoChipT, a biochip that serves as a micro-array of complex carbohydrates, designed to allow researchers to analyze glycan-protein interactions. 

Founded in 1999, the company has also developed a database of glycan sequences. The database is ordered by Glycominds'  Linear Code, a syntax and nomenclature that allows complex and diverse glycans, including any branching, linkage and/or terminal modifications, to be classified systematically.

The company expects that the database will contain some 6,000 validated sequences by the end of the year.

 

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.